Eisai Merck KEYNOTE-775 (Advanced Endometrial Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn what effects the study drugs, lenvatinib plus pembrolizumab, have on advanced endometrial cancer, when compared to standard chemotherapy.
This study is also looking if it is safe to take the drugs lenvatinib plus pembrolizumab compared to treatment with standard chemotherapy using doxorubicin or paclitaxel.
Advanced endometrial cancer
Who Can Participate in the Study?
Adult females with advanced endometrial cancer who have been treated with at least one prior chemotherapy regimen
What is Involved?
If you choose to be in this study, you will:
- Be randomized (put into one of two groups by chance like a flip of a coin) to either:
--- Group 1: lenvatinib capsules and pembrolizumab infusion (study drugs)
--- Group 2: Get either doxorubicin or paclitaxel infusions
- Get study drugs every 3 weeks for 3 cycles
- Have follow-up visits every 8 weeks with CT/MRI scans
- Be in the study for up to 3 years and have 12 or more office visits to the clinic